MYRIAD GENETICS INC

Listed Company

MYGNCIK 0000899923NasdaqAcceleratedIn Vitro & In Vivo Diagnostic SubstancesDelawareFY ends Dec 31

Period

FY 2025

Revenue

$824.50M

Net Income

$-365.90M

Total Assets

$706.60M

Equity

$368.00M

Shares Out

94.45M

Op. Cash Flow

$1.80M

MYGN$6.18+28.22% · past yearDBEQ Basic

Daily closing prices

Business

Myriad Genetics develops and commercializes molecular diagnostic tests for oncology, women's health, and mental health. The company offers hereditary cancer tests, companion diagnostics, prognostic tests, comprehensive genomic profiling, molecular residual disease testing, prenatal screening, and pharmacogenomic mental health medication testing. Myriad sells tests through direct sales and marketing in the United States and Japan, with expanding global reach through partnerships and indirect channels.

Summary from 10-K filed 2026-02-24

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Revenue	825	838	753	678	691
Cost of revenue	248	252	236	202	—
Gross profit	577	585	517	476	—
Research and development expense	107	113	89	85	82
Sales and marketing expense	281	284	289	267	—
General and administrative expense	257	276	284	248	—
Legal settlements	0	−21	113	0	—
Goodwill and long-lived asset impairment charges	319	57	0	17	2
Total operating expenses	964	709	774	617	—
Operating loss	−387	−124	−257	−141	−191
Interest income	2	2	3	3	700,000
Interest expense	−11	−3	−3	−3	—
Other	800,000	1	−4	600,000	139
Total other expense	−8	0	−5	0	133
Loss before income tax	−395	−124	−262	−141	−57
Income tax (benefit) expense	−29	4	1	−29	−30
Net loss	−366	−127	−263	−112	−27
Basic (in dollars per share)	−3.95	−1.41	−3.18	−1.39	−0.35
Diluted (in dollars per share)	−3.95	−1.41	−3.18	−1.39	−0.35
Basic (in shares)	93	91	83	81	78
Diluted (in shares)	93	91	83	81	78

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	150	102	132	57	257
Trade accounts receivable	115	121	114	102	91
Inventory	31	28	22	20	15
Prepaid taxes	12	16	17	18	18
Prepaid expenses and other current assets	25	31	19	20	21
Total current assets	333	298	314	275	485
Operating lease right-of-use assets	49	55	62	104	82
Property, plant and equipment, net	114	117	119	83	44
Intangible assets, net	153	262	350	380	404
Goodwill	52	286	287	287	239
Other assets	6	9	15	16	8
Total assets	707	1,028	1,147	1,199	1,321
Accounts payable	30	32	26	29	30
Accrued liabilities	97	119	114	94	162
Current maturities of operating lease liabilities	7	13	16	14	13
Total current liabilities	134	164	156	137	204
Unrecognized tax benefits	200,000	33	30	27	28
Long-term debt	120	40	39	0	0
Noncurrent operating lease liabilities	83	88	97	131	79
Other long-term liabilities	2	2	41	18	6
Total liabilities	339	327	363	313	353
Commitments and contingencies	—	—	—	—	—
Common stock, $0.01 par value, 93.5 and 91.3 shares outstanding at December 31, 2025, and 2024, respectively	900,000	900,000	900,000	800,000	800,000
Additional paid-in capital	1,489	1,458	1,416	1,260	1,226
Accumulated other comprehensive income (loss)	800,000	−800,000	−4	−9	−5
Accumulated deficit	−1,123	−757	−630	−366	−254
Total stockholders' equity	368	701	783	886	968
Total liabilities and stockholders equity	707	1,028	1,147	1,199	1,321

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	54	61	62	53	63
Non-cash lease expense	8	10	11	12	13
Stock-based compensation expense	35	50	41	38	36
Deferred income taxes	100,000	−3	−4	−31	−32
Unrecognized tax benefits	−33	3	3	−1	−3
Impairment of goodwill and long-lived assets	319	57	0	17	—
(Gain) loss on termination of lease	0	−3	8	0	0
Gain on acquisition	0	−2	0	0	—
Other non-cash adjustments	3	2	4	2	2
Prepaid expenses and other current assets	200,000	−4	200,000	2	−7
Trade accounts receivable	6	−9	−13	−10	−9
Inventory	−3	−6	−2	−3	2
Prepaid taxes	4	500,000	700,000	700,000	90
Other assets	2	0	600,000	−900,000	−4
Tenant improvement allowance received	0	0	16	18	0
Accounts payable	−1	5	−4	−4	9
Accrued liabilities	−28	−41	27	−86	66
Net cash provided by (used in) operating activities	2	−9	−111	−106	19
Capital expenditures	−16	−19	−63	−45	−18
Capitalization of intangible assets	−12	−11	−10	—	—
Proceeds from the sale of business, net cash sold	0	9	0	0	—
Proceeds from maturities and sales of marketable investment securities	0	9	105	128	61
Net cash (used in) provided by investing activities	−27	−12	32	−78	274
Proceeds from common stock issued under stock-based compensation plans	3	6	6	6	92
Payment of tax withheld for common stock issued under stock-based compensation plans	−7	−13	−9	−11	−12
Proceeds from underwritten public offering, net of costs and discounts	0	0	118	0	0
Proceeds from revolving credit facility	40	120	80	0	0
Repayment of revolving credit facility	−81	−120	−40	0	−226
Proceeds from the issuance of secured long-term credit facility	125	0	0	—	—
Release of cash held in escrow	−8	0	0	—	—
Other financing activities	−200,000	−400,000	−200,000	—	—
Net cash provided by (used in) financing activities	64	−7	153	−8	−151
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash	800,000	−1	600,000	−600,000	−600,000
Net increase (decrease) in cash, cash equivalents, and restricted cash	39	−29	75	−192	142

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is MYRIAD GENETICS INC's CIK number?

MYRIAD GENETICS INC's SEC CIK number is 0000899923 (899923). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find MYRIAD GENETICS INC's SEC filings?

All of MYRIAD GENETICS INC's EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did MYRIAD GENETICS INC last report earnings?

MYRIAD GENETICS INC (MYGN) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000899923-26-000036). This is MYRIAD GENETICS INC's most recent earnings filing of record — not a forecast of its next earnings date.

What is MYRIAD GENETICS INC's most recent earnings 8-K?

MYRIAD GENETICS INC's latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0000899923-26-000036. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View MYRIAD GENETICS INC's latest earnings 8-K →
Look up any company's CIK number →